Algorithmic approach for methyl-CpG binding protein 2 (MECP2) gene testing in patients with neurodevelopmental...

Area of Science:

• Genetics
• Molecular Biology
• Clinical Diagnostics

Background:

• Methyl-CpG binding protein 2 (MECP2) gene mutations cause a spectrum of neurodevelopmental disorders.
• Clinical presentations are diverse, including Rett syndrome, neonatal encephalopathy, Angelman syndrome, intellectual disability, and autism in females.

Purpose of the Study:

• To describe a gender-specific strategy for comprehensive MECP2 gene testing.
• To guide clinicians in selecting appropriate MECP2 testing based on patient phenotype and sex.

Main Methods:

• Gene sequencing of MECP2 exons 1-4 for specific phenotypes.
• Analysis for large-scale MECP2 deletions in Rett and Angelman syndrome cases with negative sequencing.
• Testing for large-scale MECP2 duplications in males with intellectual disability and specific clinical features.

Main Results:

• Sequencing is recommended for Rett syndrome, neonatal encephalopathy, Angelman syndrome (after 15q11-13 analysis), intellectual disability, and female autism.
• Deletion analysis follows negative sequencing for Rett and Angelman syndromes.
• Duplication analysis is indicated for males with intellectual disability, X-linked developmental delay, and specific symptoms like recurrent infections.

Conclusions:

• A tailored, gender-specific testing approach optimizes the diagnostic yield of MECP2 gene analysis.
• Accurate MECP2 testing is essential for diagnosing complex neurodevelopmental conditions.